Pollogen

Company Overview

Snapshot

Founded in June 2006 by Zion Azar, Pollogen operated with 51–200 employees. The company was acquired by Lumenis in November 2015, marking a significant exit in the medical aesthetics sector.

Business overview

Pollogen develops and manufactures non-invasive, minimally invasive, and non-surgical solutions for medical aesthetics professionals. The company's product portfolio addresses concerns such as acne scars, cellulite reduction, facial contouring, skin rejuvenation, and wrinkle reduction, serving the global health tech and life sciences markets with brands like OxyGeneo, TriPollar, and VoluDerm.

Strategic signal

In August 2019, Pollogen's TriPollar Stop home-use device received FDA clearance. This regulatory approval signals strong product validation and expands market access, indicating the company's continued commitment to bringing its aesthetic technologies to a broader consumer base even after its acquisition.

Company Intelligence Q&A

When was Pollogen acquired?

Pollogen was acquired by Lumenis in November 2015.

What is Pollogen's core business?

Pollogen provides safe, effective, and painless solutions designed to enhance the practices of medical esthetics professionals, focusing on noninvasive, minimally invasive, and nonsurgical treatments for various skin concerns.

Which Pollogen product received FDA clearance?

Pollogen's leading home-use device, TriPollar Stop, received FDA clearance in August 2019.

What new product did Pollogen expand its portfolio with in 2016?

In November 2016, Pollogen, a Lumenis-owned company, expanded its portfolio with the Divine Pro, a holistic approach to repair the signs of aging.

What was the focus of a clinical study on Pollogen's technology in 2016?

In June 2016, a clinical comparative study showed that Hybrid Energy (VoluDerm HE) Micro-needle RF Technology by Pollogen is a safer and more tolerable treatment option for the aging neck with minimal pain and no downtime.